Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with confirmed diagnosis of Type2 diabetes mellitus (T2DM) by standard criteria~* C-peptide \>0.6 ng/ml (\>0.20 nmol/L).~* HbA1c ≥7.5 to ≤11% at Visit 1~* Treatment with stable, once or twice daily doses (maximum dose of \< 1 unit/kg/day) of basal (long-acting, intermediate-acting) insulin alone or pre-mixed insulin for at least 12 weeks prior to Visit 1. Stable is defined as ±10% of the Visit 1 dose during the previous 12 weeks~* Patients receiving metformin must be on a stable dose of metformin (at least 1500 mg daily or a maximally tolerated dose) for at least 12 weeks prior to Visit 1~* Body Mass Index (BMI) ≥20 to ≤40 kg/m2 at Visit~Exclusion Criteria:~Patients fulfilling any of the following criteria are not eligible for participation in the study~* Fasting plasma glucose (FPG) ≥240 mg/dl (13.3 mmol/L) at Visit 1~* Pregnant or lactating women~* Acute metabolic diabetes complications such as ketoacidosis or hyperosmolar state (coma) within the past 6 months~* Current diagnosis of congestive heart failure (NYHA III or IV).~* Myocardial infarction (MI) within the past 6 months~* Liver disease such as cirrhosis or chronic active hepatitis~Other protocol defined inclusion/excusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (Type: EXPERIMENTAL): Eligible patients will receive vildagliptin 50 mg in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Eligible patients will receive matching placebo in addition to their stable dose of insulin with or without metformin. One tablet should be taken twice daily as one tablet before breakfast meal and one tablet before the evening meal for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).